Asymmetric dimethylarginine predicts outcome and time of stay in hospital in patients attending an internal medicine emergency room

Clinica Chimica Acta

Volumn 401, Issue 1-2, 2009, Pages 20-24

  Schulze, Friedrich ^a   Vollert, Jörn ^b   Maas, Renke ^c   Müller, Reinhold ^b   Schwedhelm, Edzard ^a   Müller, Christian ^b   Böger, Rainer H ^a   Möckel, Martin ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Asymmetric dimethylarginine; Cardiovascular disease; Emergency room; Outcome; Risk factor; Time of stay

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; AGED; ARGININE; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT;

EID: 58549101271     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.10.031     Document Type: Article

References (21)

1. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
2. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24 (2004) 1023-1030
3. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38 (2006) 126-136
4. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
5. Schulze F., Lenzen H., Hanefeld C., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 152 (2006) 493.e1-493.e8
6. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
7. Maas R., Schulze F., Baumert J., et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 53 (2007) 693-701
8. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
9. Zoccali C., Bode-Böger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
10. Maas R., Dentz L., Schwedhelm E., et al. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med 35 (2007) 1876-1881
11. Nijveldt R.J., Teerlink T., Van Der Hoven B., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22 (2003) 23-30
12. Downing A., and Wilson R. Temporal and demographic variations in attendance at accident and emergency departments. Emerg Med J 19 (2002) 531-535
13. Aminzadeh F., and Dalziel W.B. Older adults in the emergency department: a systematic review of patterns of use, adverse outcomes, and effectiveness of interventions. Ann Emerg Med 39 (2002) 238-247
14. Downing A., Wilson R.C., and Cooke M.W. Which patient spend more than 4 hours in the accident and emergency department?. J Public Health 26 (2004) 172-176
15. Schulze F., Wesemann R., Schwedhelm E., et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 42 (2004) 1377-1383
16. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., and Böger R.H. Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects. Eur J Clin Invest 35 (2005) 622-626
17. Leong T., Zylberstein D., Graham I., et al. Swedish-Irish-Norwegian Collaboration. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 28 (2008) 961-967
18. Tisdale M.J. Cachexia in cancer patients. Nature 2 (2002) 862-870
19. Habbu A., Lakkis N.M., and Dokainish H. The obesity paradox: fact or fiction?. Am J Cardiol 98 (2006) 944-948
20. Kostourou V., Robinson S.P., Cartwright J.E., and Whitley G.S. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 87 (2002) 673-680
21. Kostourou V., Robinson S.P., Whitley G.S., and Griffiths J.R. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 63 (2003) 4960-4966